目的：：探讨帕利哌酮治疗首发精神分裂症患者的临床疗效与安全性。方法：将62例首发精神分裂症患者随机分为帕利哌酮组和奥氮平组，每组各31例。帕利哌酮组患者给予帕利哌酮缓释片治疗，奥氮平组患者给予奥氮平治疗。两组患者治疗8周后，采用阳性与阴性症状量表(PANSS)评定疗效，采用治疗中出现的症状量表(TESS)评定不良反应。结果：帕利哌酮组患者的治疗总有效率为87.1%，奥氮平组患者的治疗总有效率为83.9%，两组患者疗效差异无显著性(P>0.05)，帕利哌酮组患者的体重增加、嗜睡和便秘显著少于奥氮平组(P<0.05)，锥体外系反应明显高于奥氮平组(P<0.05)。结论：两组患者疗效相当，均为疗效好、安全性高的抗精神病药，但要注意其锥体外系不良反应。%Objective:To explore efficacy and safety of Paliperidone in treatment of patients with first-episode schizophrenia. Methods:62 cases of patients with schizophrenia were divided into two groups with 31 cases in each group, being treated with Paliper-idone or Olanzapine for 8 weeks, respectively. The positive and negative symptom scale ( PANSS) and treatment emergent symptom scale ( TESS) were used to evaluate the efficacy and adverse reaction, respectively. Results:The total effective rates of Paliperidone group and Olanzapine group were 87. 1% and 83. 9%, respectively, and there was no significant difference between the two groups (P>0.05). The weight gain, drowsiness and constipation of Paliperidone group was significantly less than the Olanzapine group (P>0. 05);however, the extrapyramidal side effects of Olanzapine group were significantly decreased (P<0. 05). Conclusions:Paliperi-done and Olanzapine are effective and safe antipsychotic drugs, but the doctors should pay attention to extrapyramidal side effects of Paliperidone.
展开▼
